Possible explanations for the poor effect of PD-L1 inhibitors in EGFR-mutated NSCLC could be the small number of CD8+ tumor-infiltrating lymphocytes and the low tumor mutational burden of these tumors, which is associated with a limited number of neoantigens and thus a lower likelihood of response to ICIs.99 This evidence concerns the gene EGFR and non-small cell lung carcinoma.